Email Updates

You are here

Home»Media

AVAC in the News

  • AIDS `Next Big Thing' Rests on Study of Gilead Disease Prevention Cocktail

    Gilead Sciences Inc. may learn this year whether its drugs for treating HIV can also stop people from catching the virus in the first place. The approach may help curb the AIDS pandemic in poor countries and bring Gilead $1 billion a year in additional U.S. sales, said Josh Schimmer, an analyst at Leerink Swann & Co. in Boston. Most investors aren’t alert to the potential benefit, he said. Researchers are compiling the first data from 10 trials involving more than 20,000 people, and initial results may be available in July.

    April 1, 2010
    Treatment
    Bloomberg

  • AIDS Prevention Gel Fails in Trial, Researchers Say

    Researchers said the failure of the microbicide gels in a trial in South Africa, Zambia, Uganda and Tanzania was the last nail in the coffin for this type of prevention method.

    December 15, 2009
    Microbicides
    New York Times

  • A gel against HIV fails, disappointing researchers

    An antimicrobial gel tested as a method to curb the spread of HIV just proved ineffective in a major human study.

    December 14, 2009
    Microbicides
    NPR

  • Celebrating the possible in the fight against AIDS

    A decade of increasing funding for HIV programs - in prevention, treatment and research - is paying off. Ironically, though, this good news comes at the same time that the global economic crisis and political arguments threaten the future of HIV funding.

    November 30, 2009
    Huffington Post

  • Thai HIV vaccine study: modest effect is real, argue researchers

    The modest protective effect of the HIV vaccine combination used in the Thai vaccine trial announced last month is statistically significant and not the result of massaging the statistics to produce a positive result, study investigators said at the AIDS Vaccine 2009 conference in Paris today.

    October 20, 2009
    HIV Vaccine
    aidsmap

  • AIDS vaccine study reassures skeptics

    The fog around the largest AIDS vaccine study ever conducted began to lift today, as Thai and U.S. researchers for the first time publicly presented a detailed analysis of their data to over 1000 scientists gathered here at an annual meeting.

    October 20, 2009
    HIV Vaccine
    Science Insider

  • Data Call Into Question HIV Study Results

    Researchers from the U.S. Army and Thailand announced last month they had found the first vaccine that provided some protection against HIV. But a second analysis of the $105 million study, not disclosed publicly, suggests the results may have been a fluke, according to AIDS scientists who have seen it.

    October 12, 2009
    HIV Vaccine
    Wall Street Journal

  • For first time, AIDS vaccine shows some success

    The vaccine — known as RV 144, a combination of two genetically engineered vaccines, neither of which had worked before in humans — was declared a qualified success after a six-year clinical trial on more than 16,000 volunteers in Thailand. Those who were vaccinated became infected at a rate nearly one-third lower than the others, the sponsors said Thursday morning.

    September 24, 2009
    HIV Vaccine
    New York Times

  • New Web Site Seeks to Fight Myths About Circumcision and H.I.V.

    Trying to fight misconceptions about the link between H.I.V. transmission and circumcision.

    March 3, 2009
    Voluntary Medical Male Circumcision
    New York Times

  • Indevus' sex gel shows first AIDS protection in women

    A vaginal gel made by Indevus Pharmaceuticals Inc. showed first signs that such a product might protect women from the AIDS virus.

    February 9, 2009
    Microbicides
    Bloomberg

Pages